Drug Profile
Research programme: avian influenza virus antibody therapy - OMRIX Biopharmaceuticals
Alternative Names: Avian Influenza IG - OMRIX BiopharmaceuticalsLatest Information Update: 03 Dec 2012
Price :
$50
*
At a glance
- Originator OMRIX Biopharmaceuticals
- Class Antibodies; Immunoglobulins
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Influenza virus infections
Most Recent Events
- 03 Dec 2012 Discontinued - Preclinical for Influenza virus infections in USA (Parenteral)
- 30 Dec 2008 OMRIX Biopharmaceuticals has been acquired by Johnson and Johnson
- 10 Oct 2006 Preclinical trials in Influenza virus infections in USA (Parenteral)